How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?

European Respiratory Journal

Volumn 45, Issue 2, 2015, Pages 549-554

  Qin, Zhi Zhen ^a   Pai, Madhukar ^a   Van Gemert, Wayne ^b   Sahu, Suvanand ^c   Ghiasi, Marzieh ^a   Creswell, Jacob ^c  

^a MCGILL UNIVERSITY   (Canada)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Stop TB Partnership   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; DIAGNOSTIC KIT; NUCLEIC ACID;

AFGHANISTAN; BANGLADESH; BRAZIL; CAMBODIA; CHINA; DEMOCRATIC REPUBLIC CONGO; DISEASE ASSOCIATION; DRUG SENSITIVITY; ETHIOPIA; EXTRAPULMONARY TUBERCULOSIS; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INDIA; INDONESIA; KENYA; LETTER; MOLECULAR DIAGNOSTICS; MOZAMBIQUE; MULTIDRUG RESISTANT TUBERCULOSIS; MYANMAR; NIGERIA; PAKISTAN; PHILIPPINES; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROTOCOL COMPLIANCE; PUBLIC-PRIVATE PARTNERSHIP; RISK FACTOR; RUSSIAN FEDERATION; SOUTH AFRICA; TANZANIA; THAILAND; TUBERCULOSIS; TUBERCULOSIS CONTROL; UGANDA; VIET NAM; WORLD HEALTH ORGANIZATION; ZIMBABWE; ALGORITHM; COMPLICATION; DIAGNOSTIC KIT; HIV INFECTIONS; MOLECULAR DIAGNOSIS; POINT OF CARE TESTING; PROCEDURES; QUESTIONNAIRE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ALGORITHMS; HEALTH POLICY; HIV INFECTIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACIDS; POINT-OF-CARE TESTING; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; SOUTH AFRICA; SURVEYS AND QUESTIONNAIRES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

EID: 84961292032     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00147714     Document Type: Letter

References (15)

1. World Health Organization. Global tuberculosis report 2013. Geneva, WHO, 2013.
2. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, WHO, 2011.
3. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. Geneva, WHO, 2013.
4. World Health Organization. WHO monitoring of Xpert MTB/RIF roll-out 2014. www.stoptb.org/wg/gli/assets/documents/map/1/atlas.html Date last accessed: July 21, 2014.
5. Kik SV, Denkinger CM, Chedore P, et al. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential?. Eur Respir J 2014;43:1793-1796.
6. World Health Organization. 6th Global Laboratory Initiative (GLI) Partners Meeting 2014. www.stoptb.org/wg/gli/assets/html/6th%20GLI%20meeting%20AGENDA-for%20WEBSITE.htm.
7. Creswell J, Codlin AJ, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis 2014;14:2.
8. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013;42:252-271.
9. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014;383:424-35.
10. Denkinger CM, Nicolau I, Ramsay A, et al. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics?. Eur Respir J 2013;42:544-547.
11. Stop TB Partnership. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. Geneva, WHO, 2010.
12. World Health Organization. Sixty-Seventh World Health Assembly. A67/11. Draft global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva, WHO, 2014.
13. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision. Geneva, WHO, 2013.
14. Van Deun A, Maug AK, Bola V, et al. Rifampicin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013;51:2633-2640.
15. Salje H, Andrews JR, Deo S, et al. The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model. PLoS Med 2014;11:e1001674.